Topics

Tear Film Innovations, Inc. Company Profile

14:47 EDT 19th September 2019 | BioPortfolio

Tear Film Innovations (TFI) is an early-stage company developing break-through products for the treatment of evaporative dry eye and related syndromes including Meibomian Gland Dysfunction (MGD) and blepharitis. For more information visit www.tearfilm.com.


News Articles [549 Associated News Articles listed on BioPortfolio]

Johnson & Johnson Vision to Showcase New Data and Innovations in Eye Care at the 2019 BCLA Conference

- Clinical data to be presented on enhancing visual comfort with a first-of-its-kind innovation, the integration of tear film components with contact lenses, and more - Eye care professionals invi...

Neurostimulation for Tear Production

A recently developed intranasal tear neurostimulator may provide a new option for dry eye treatment. Current Opinion in Ophthalmology

Oyster Point Pharma Scores $93 Million Series B to Focus Its Gaze on Dry Eye Disease

The company’s two lead product candidates are OC-01 and OC-02, which are delivered by way of an ocular surface-sparing nasal spray that stimulates the trigeminal parasympathetic pathway to induce na...

"How I Live"- a film about childhood cancers

At the GHCS meeting in Boston, ecancer spoke with the makers of "How I Live", a film about childhood cancer. The film follows the lives of five families from low and middle income countries, located ...

Oyster Point Pharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today a...

Film trailer towards gene editing in humans

Here’s a film trailer of the documentary Human Nature that looks at a future of gene editing[1] – The film is to be released soon in Australia and elsewhere. Here’s their blurb, The biggest ...

Oyster Point Pharma to Present at the Cowen and Company 39th Annual Health Care Conference

Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today a...

Show Me Consent! - Call For Entries To Short Film Festival

SEATTLE (PRWEB) August 06, 2019 The Consent Academy is proud to present its first-ever film festival, “Show Me Consent.” A...

PubMed Articles [721 Associated PubMed Articles listed on BioPortfolio]

Clinical and biochemical analysis of the ageing tear film.

Tear film stability is important for healthy visual function, and yet little is known of the ageing mechanisms. The aim of this study was to investigate parallels between biochemical changes and clini...

Inferior Quadrant of Tear Film Is More Likely to Break and Breaks Early in Patients With Dry Eyes.

To investigate the temporal and spatial distribution of tear film breakup time via a noninvasive topographer in normal subjects and patients with dry eye disease (DED).

Differences in Meibum and Tear Lipid Composition and Conformation.

The compositional, structural, and functional relationships of meibum may provide insights into the loss of tear film stability. Although the conformation of meibum lipids has been studied rigorously,...

Noninvasive evaluation of anterior segment and tear film parameters and morphology of meibomian glands in a pediatric population with hypogonadism.

To compare the meibomian gland (MG), non-invasive tear film break-up time (NITFBUT), anterior segment measurements between healthy children and children with hypogonadism.

A New Perspective on Dry Eye Classification: Proposal by the Asia Dry Eye Society.

The 2017 consensus report of the Asia Dry Eye Society (ADES) on the definition and diagnosis of dry eyes described dry eye disease as "Dry eye is a multifactorial disease characterized by unstable tea...

Clinical Trials [619 Associated Clinical Trials listed on BioPortfolio]

Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy

Dry Eye Syndrome (DES) is a disease affects the production and stability of the tear film, leading to vision disturbances and a major decrease in quality of life. The most recommended trea...

Optical Coherence Tomography of Tear Film Dynamics In-Vivo

The purpose of this study is to evaluate a new instrument that takes digital images of tear film (a thin film that coats the eye that is made up of oil and water). The investigators are i...

Evaluation of Tear Film Lipid Layer Thickness Change After Cataract Surgery

This study will compare cataract patients before and after phacoemulsification. Evaluations will be performed before and 1 and 3 months following cataract surgery, including measurement of...

A Prospective Clinical Study Assessing the Effects of Tetracycline Antibiotic on Tear Film and Tear Lipid Composition Within a Population of Patients Diagnosed With Blepharitis and Dry Eye Disease

The purpose of this research project is to determine the effects of oral tetracycline such as Minocycline (Minocin) on tear film composition and tear lipid (meibomian gland secretions) cha...

Tear Film Break-up Time After Instillation of Artificial Tears

This study is an exploratory trial evaluating the tear film break-up time after a single eye drop instillation of over-the-counter artificial tears. The primary hypothesis is that tear fil...

Companies [590 Associated Companies listed on BioPortfolio]

Tear Film Innovations, Inc.

Tear Film Innovations (TFI) is an early-stage company developing break-through products for the treatment of evaporative dry eye and related syndromes including Meibomian Gland Dy...

TearScience®, Inc.

Headquartered in Morrisville, North Carolina, TearScience® has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the m...

Oyster Point Pharma, Inc.

Based in Princeton, New Jersey, Oyster Point is a clinical-stage pharmaceutical company leveraging neuroscience to discover, develop, and commercialize novel therapies to treat di...

Mati Therapeutics Inc.

Mati is developing PPDS, a sustained release ocular drug delivery platform that Mati believes has the potential to treat a range of ocular indications. The platform utilizes a dev...

TearScience

Headquartered in Morrisville, North Carolina, TearScience has pioneered devices that provide significant clinical improvement in the treatment of evaporative dry eye. Of the more ...

More Information about "Tear Film Innovations, Inc." on BioPortfolio

We have published hundreds of Tear Film Innovations, Inc. news stories on BioPortfolio along with dozens of Tear Film Innovations, Inc. Clinical Trials and PubMed Articles about Tear Film Innovations, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tear Film Innovations, Inc. Companies in our database. You can also find out about relevant Tear Film Innovations, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record